Literature DB >> 15906860

[Some consequences of systemic inflammatory response in the pathogenesis of aggravation of outcomes of combined radiation and thermal injuries].

R S Budagov, L P Ul'ianova.   

Abstract

Experiments were executed on (CBA x C57BL6) F1 male mice. Animals were subjected to the total body irradiation with a dose 7 Gy or combine radiation-thermal injury (CRTI), when irradiated animals were additionally subjected to a thermal burn of 10% of the body surface. Some signs of systemic inflammatory response were investigated in these two compared groups. It was established that the period of substantial increasing of the mortality in animals with CRTI (from 7th till 15th day) was characterized with expressed postradiation leikopenia and thrombocytopenia, was accompanied by hypoalbuminemia and hyperfibrinogenemia with a moderate raise in serum ALT activity. From all investigated hematological and biochemical parameters, at CRTI only plasma level of fibrinogen statistically differed from that in a group of the irradiated mice without a burn. It is suggested that endogenous infection and bacterial toxins are important at the pathogenesis of hyperfibrinogenemia and aggravation of CRTI outcomes by the 30-days survival criteria.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15906860

Source DB:  PubMed          Journal:  Radiats Biol Radioecol        ISSN: 0869-8031


  2 in total

Review 1.  Ghrelin as a novel therapy for radiation combined injury.

Authors:  Asha Jacob; Kavin G Shah; Rongqian Wu; Ping Wang
Journal:  Mol Med       Date:  2010-01-19       Impact factor: 6.354

2.  Serum albumin level as a risk factor for mortality in burn patients.

Authors:  Olivia Alejandra Aguayo-Becerra; Carlos Torres-Garibay; Michel Dassaejv Macías-Amezcua; Clotilde Fuentes-Orozco; Mariana de Guadalupe Chávez-Tostado; Elizabeth Andalón-Dueñas; Arturo Espinosa Partida; Andrea Del Socorro Alvarez-Villaseñor; Ana Olivia Cortés-Flores; Alejandro González-Ojeda
Journal:  Clinics (Sao Paulo)       Date:  2013-07       Impact factor: 2.365

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.